相关实验视频
Updated: Nov 19, 2025

12:59
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
35.1K
针对牛皮的IL-23和IL-17途径的治疗方法
Kamran Ghoreschi1, Anna Balato2, Charlotta Enerbäck3
1Department of Dermatology, Venereology, and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany; Charité-Universitätsmedizin Berlin, Berlin, Germany.
Lancet (London, England)
|January 30, 2021
概括
牛皮是一种慢性炎症性皮肤疾病,通过阻断IL-23和IL-17途径有效治疗. 针对这一途径的新疗法在治疗牛皮和相关疾病方面表现有前途.
科学领域:
- 免疫学
- 皮肤病学
- 翻译医学
背景情况:
- 牛皮是一种慢性炎症性皮肤疾病,影响全球人口的2-3%,其特点是皮肤病变和全身性影响.
- 这种疾病涉及质细胞的过度增殖和分化问题,由IL-23和IL-17途径免疫媒介驱动.
研究的目的:
- 通过转化免疫学了解和治疗牛皮的进展.
- 突出针对IL-23/IL-17途径在牛皮治疗中的有效性.
主要方法:
- 目前关于牛皮病原和治疗的文献综述.
- 针对IL-23和IL-17途径的已批准和正在研究的治疗方法的分析.
主要成果:
- 向IL-23/IL-17途径已经导致成功治疗牛皮,具有显著的临床疗效.
- 针对IL-23,IL-17和IL-17RA的已批准的生物药物表现出极好的结果.
- 细胞内途径抑制剂 (例如TYK2,RORγt) 正在临床开发中.
结论:
- 该IL-23/IL-17途径是治疗牛皮的有效标,具有显著的治疗成功.
- 虽然对皮肤和牛皮关节炎症状有效,但长期疾病修饰和并发性影响需要进一步研究.
相关概念视频
T Cell Types and Functions
1.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
295
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
295
The JAK-STAT Signaling Pathway
10.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.3K
Inflammatory Bowel Disease IV: Pharmacological Management
300
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
300
iPS Cell Differentiation
2.9K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.9K
Drugs for Treatment of Ulcerative Colitis in IBD
306
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
306

